2020 Nine Months Report

The Board of Directors of Farmaceutica REMEDIA S.A. informs that the Report for the 3rd Quarter of 2020, consolidated – the full version – is available on its own website  http://www.remedia.ro and  in the link http://www.remedia.ro/en/investors-2-2/company-financials/

During 01.01.2020 – 30.09.2020, the commercial company Farmaceutica REMEDIA S.A. recorded the following consolidated financial results:

The economic – financial indicators on 30.09.2020 are presented in the following table:

Notes:

1) Current liquidity – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors in case of FR, certifying that the company is able to cover their short-term debts based on receivables and cash availabilities.

2) Degree of indebtedness expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. In the case of both companies there is no risk. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

3) Turnover speed for client debit items expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of the indicator is normal for the both companies, under the circumstances.

4) The value of the No. of storage Days indicator can be considered as falling within the specifics of the activity.

Chairman of the Board of Administrators,
TARUS” – Valentin Norbert TARUS e.U.

Share this post
Share on facebook
Share on twitter
Share on linkedin

Related news

PRESS RELEASE

In compliance with the legal provisions in force on issuers and securities operations, the Board of Administrators of the Commercial Company Farmaceutica REMEDIA S.A. informs

Press release Bursa

In compliance with the legal provisions in force on issuers and securities operations, the Board of Administrators of the Commercial Company Farmaceutica REMEDIA S.A. informs